Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation
Low grade serous ovarian cancer (LGSOC) is a slowly growing, relatively chemoresistant neoplasm that is associated with a more favorable prognosis, especially compared to the disease's high-grade serous counterpart. We recount a case involving a 47-year-old, heavily pretreated LGSOC patient who...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-11-01
|
| Series: | Gynecologic Oncology Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578918300870 |
| _version_ | 1819242112399441920 |
|---|---|
| author | Alberto A. Mendivil Paul K. Tung Randy Bohart Karen Bechtol Bram H. Goldstein |
| author_facet | Alberto A. Mendivil Paul K. Tung Randy Bohart Karen Bechtol Bram H. Goldstein |
| author_sort | Alberto A. Mendivil |
| collection | DOAJ |
| description | Low grade serous ovarian cancer (LGSOC) is a slowly growing, relatively chemoresistant neoplasm that is associated with a more favorable prognosis, especially compared to the disease's high-grade serous counterpart. We recount a case involving a 47-year-old, heavily pretreated LGSOC patient who presented with an elevated CA-125 of 1047 U/mL during her recent course of pemetrexed therapy. Thereafter, she underwent molecular profiling, which revealed a BRAF V600E mutation; accordingly, the patient was administered dabrafenib and trametinib combination therapy, a regimen that resulted in a precipitous decline of her CA-125 to 35 U/mL following the 6th cycle. The patient's favorable response to BRAF and MEK 1/2 inhibitor therapy underscores the significance of molecular profile testing and the use of targeted therapy regardless of tissue origin, especially in cases for whom standard management is limited or ineffective. Keywords: Low grade serous ovarian cancer, BRAF mutation, Dabrafenib, Trametinib |
| first_indexed | 2024-12-23T14:34:37Z |
| format | Article |
| id | doaj.art-fe9b4aa206cf4e0f890c3511ba716da1 |
| institution | Directory Open Access Journal |
| issn | 2352-5789 |
| language | English |
| last_indexed | 2024-12-23T14:34:37Z |
| publishDate | 2018-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gynecologic Oncology Reports |
| spelling | doaj.art-fe9b4aa206cf4e0f890c3511ba716da12022-12-21T17:43:24ZengElsevierGynecologic Oncology Reports2352-57892018-11-01264144Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutationAlberto A. Mendivil0Paul K. Tung1Randy Bohart2Karen Bechtol3Bram H. Goldstein4Gynecologic Oncology Associates, Newport Beach, CA 92663, United StatesUniversity of California, Irvine, Department of Radiological Sciences, 1001 Health Sciences Road, Irvine, CA 92697-3950, United StatesOso Home Care, 17175 Gillette Avenue, Irvine, CA 92614, United StatesGynecologic Oncology Associates, Newport Beach, CA 92663, United StatesGynecologic Oncology Associates, Newport Beach, CA 92663, United States; Corresponding author at: Gynecologic Oncology Associates, 351 Hospital Road, Suite 507, Newport Beach, CA 92663, United States.Low grade serous ovarian cancer (LGSOC) is a slowly growing, relatively chemoresistant neoplasm that is associated with a more favorable prognosis, especially compared to the disease's high-grade serous counterpart. We recount a case involving a 47-year-old, heavily pretreated LGSOC patient who presented with an elevated CA-125 of 1047 U/mL during her recent course of pemetrexed therapy. Thereafter, she underwent molecular profiling, which revealed a BRAF V600E mutation; accordingly, the patient was administered dabrafenib and trametinib combination therapy, a regimen that resulted in a precipitous decline of her CA-125 to 35 U/mL following the 6th cycle. The patient's favorable response to BRAF and MEK 1/2 inhibitor therapy underscores the significance of molecular profile testing and the use of targeted therapy regardless of tissue origin, especially in cases for whom standard management is limited or ineffective. Keywords: Low grade serous ovarian cancer, BRAF mutation, Dabrafenib, Trametinibhttp://www.sciencedirect.com/science/article/pii/S2352578918300870 |
| spellingShingle | Alberto A. Mendivil Paul K. Tung Randy Bohart Karen Bechtol Bram H. Goldstein Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation Gynecologic Oncology Reports |
| title | Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation |
| title_full | Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation |
| title_fullStr | Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation |
| title_full_unstemmed | Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation |
| title_short | Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation |
| title_sort | dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a braf v600e mutation |
| url | http://www.sciencedirect.com/science/article/pii/S2352578918300870 |
| work_keys_str_mv | AT albertoamendivil dramaticclinicalresponsefollowingdabrafenibandtrametinibtherapyinaheavilypretreatedlowgradeserousovariancarcinomapatientwithabrafv600emutation AT paulktung dramaticclinicalresponsefollowingdabrafenibandtrametinibtherapyinaheavilypretreatedlowgradeserousovariancarcinomapatientwithabrafv600emutation AT randybohart dramaticclinicalresponsefollowingdabrafenibandtrametinibtherapyinaheavilypretreatedlowgradeserousovariancarcinomapatientwithabrafv600emutation AT karenbechtol dramaticclinicalresponsefollowingdabrafenibandtrametinibtherapyinaheavilypretreatedlowgradeserousovariancarcinomapatientwithabrafv600emutation AT bramhgoldstein dramaticclinicalresponsefollowingdabrafenibandtrametinibtherapyinaheavilypretreatedlowgradeserousovariancarcinomapatientwithabrafv600emutation |